In this article

LLY

NOVO.B-DK

Follow your favorite stocks CREATE FREE ACCOUNT

Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medications: pills.

Both companies expect to launch oral obesity drugs in the U.S. next year, once regulators approve them. Daily pills could introduce more people to GLP-1s, the class of medicine that's best known for weekly shots.

But after Lilly's pill produced less weight loss than analysts had expected in a recent late-stage trial , it raised new questions about how widely the oral drugs will be adopted and which rival company will dominate the space.

Doctors will get a closer look at how Lilly and Novo's pills compare in the coming months when Lilly releases the results of a head-t

See Full Page